Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Drug Review Costs Still Largely Non-Personnel Related

Executive Summary

Despite a recent hiring binge, FDA's ANDA evaluation expenses continue to be driven by infrastructure and equipment.

You may also be interested in...



US FDA Personnel Costs Drop: Is The Next Generation Taking Over?

The agency sees its personnel compensation and benefits costs decrease for the first time in at least 16 years, while the overall FTE count continues to rise.

US FDA Personnel Costs Drop: Is The Next Generation Taking Over?

The agency sees its personnel compensation and benefits costs decrease for the first time in at least 16 years, while the overall FTE count continues to rise.

PDUFA Workload Sets Records, But Inflation Generates More Revenue

The PDUFA revenue inflation adjustment was higher than the workload adjustment for the first time in seven years.

Related Content

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel